Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems

Shinya Hiramitsu, Yoshiaki Ishiguro, Hiroyuki Matsuyama, Kenji Yamada, Kazuo Kato, Manji Noba, Akihisa Uemura, Yoshirou Matsubara, Satoshi Yoshida, Atsushi Kani, Mamoru Tokuda, Hisashi Kato, Kazuo Hasegawa, Tatsushi Uchiyama, Shiro Matsubara, Kazuma Mori, Hisashi Kimura, Kenji Shino, Yasuchika Kato, Junichi Ishii

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Hyperuricemia is increasing in prevalence and this is paralleled by an increased incidence of acute gout. In addition, there is growing evidence of an association between high serum levels of uric acid (sUA) and cardiovascular disease (CVD). In this preliminary report, we present 12-16 week results from a multicenter, general practice study in which we evaluated the usefulness of febuxostat in a cohort of untreated patients with hyperuricemia with a high prevalence of CVD. Febuxostat titrated from 10 mg/day up to 40 mg/day resulted in statistically significant and clinically relevant reductions in sUA after 12-16 weeks. A "responder" level of 6.0 mg/dL or lower was achieved in 95 of 100 (95%) patients. Significant reductions in sUA were achieved regardless of the presence/absence of coexisting diseases (e.g. CVD, renal insufficiency, diabetes and obesity) or the class of antihypertensive agent being used by the patient. No serious adverse reactions were noted with febuxostat. Although allopurinol has been used generally for hyperuricemia/gout, it is excreted fully via the kidneys, restricting its use in patients with reduced renal function, and its three-times-daily administration leads to poor adherence. Based on the results of this study, febuxostat may provide an easier option than allopurinol for clinicians specializing in CVDs.

Original languageEnglish
Pages (from-to)433-440
Number of pages8
JournalClinical and Experimental Hypertension
Volume36
Issue number6
DOIs
Publication statusPublished - 01-10-2014

Fingerprint

Hyperuricemia
General Practice
Tablets
Uric Acid
Allopurinol
Cardiovascular Diseases
Gout
Serum
Kidney
Antihypertensive Agents
Renal Insufficiency
Obesity
Febuxostat
Incidence

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Physiology

Cite this

Hiramitsu, Shinya ; Ishiguro, Yoshiaki ; Matsuyama, Hiroyuki ; Yamada, Kenji ; Kato, Kazuo ; Noba, Manji ; Uemura, Akihisa ; Matsubara, Yoshirou ; Yoshida, Satoshi ; Kani, Atsushi ; Tokuda, Mamoru ; Kato, Hisashi ; Hasegawa, Kazuo ; Uchiyama, Tatsushi ; Matsubara, Shiro ; Mori, Kazuma ; Kimura, Hisashi ; Shino, Kenji ; Kato, Yasuchika ; Ishii, Junichi. / Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems. In: Clinical and Experimental Hypertension. 2014 ; Vol. 36, No. 6. pp. 433-440.
@article{0de47f82bdca44df9a7166c174eed101,
title = "Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems",
abstract = "Hyperuricemia is increasing in prevalence and this is paralleled by an increased incidence of acute gout. In addition, there is growing evidence of an association between high serum levels of uric acid (sUA) and cardiovascular disease (CVD). In this preliminary report, we present 12-16 week results from a multicenter, general practice study in which we evaluated the usefulness of febuxostat in a cohort of untreated patients with hyperuricemia with a high prevalence of CVD. Febuxostat titrated from 10 mg/day up to 40 mg/day resulted in statistically significant and clinically relevant reductions in sUA after 12-16 weeks. A {"}responder{"} level of 6.0 mg/dL or lower was achieved in 95 of 100 (95{\%}) patients. Significant reductions in sUA were achieved regardless of the presence/absence of coexisting diseases (e.g. CVD, renal insufficiency, diabetes and obesity) or the class of antihypertensive agent being used by the patient. No serious adverse reactions were noted with febuxostat. Although allopurinol has been used generally for hyperuricemia/gout, it is excreted fully via the kidneys, restricting its use in patients with reduced renal function, and its three-times-daily administration leads to poor adherence. Based on the results of this study, febuxostat may provide an easier option than allopurinol for clinicians specializing in CVDs.",
author = "Shinya Hiramitsu and Yoshiaki Ishiguro and Hiroyuki Matsuyama and Kenji Yamada and Kazuo Kato and Manji Noba and Akihisa Uemura and Yoshirou Matsubara and Satoshi Yoshida and Atsushi Kani and Mamoru Tokuda and Hisashi Kato and Kazuo Hasegawa and Tatsushi Uchiyama and Shiro Matsubara and Kazuma Mori and Hisashi Kimura and Kenji Shino and Yasuchika Kato and Junichi Ishii",
year = "2014",
month = "10",
day = "1",
doi = "10.3109/10641963.2013.846358",
language = "English",
volume = "36",
pages = "433--440",
journal = "Clinical and Experimental Hypertension",
issn = "1064-1963",
publisher = "Informa Healthcare",
number = "6",

}

Hiramitsu, S, Ishiguro, Y, Matsuyama, H, Yamada, K, Kato, K, Noba, M, Uemura, A, Matsubara, Y, Yoshida, S, Kani, A, Tokuda, M, Kato, H, Hasegawa, K, Uchiyama, T, Matsubara, S, Mori, K, Kimura, H, Shino, K, Kato, Y & Ishii, J 2014, 'Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems', Clinical and Experimental Hypertension, vol. 36, no. 6, pp. 433-440. https://doi.org/10.3109/10641963.2013.846358

Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems. / Hiramitsu, Shinya; Ishiguro, Yoshiaki; Matsuyama, Hiroyuki; Yamada, Kenji; Kato, Kazuo; Noba, Manji; Uemura, Akihisa; Matsubara, Yoshirou; Yoshida, Satoshi; Kani, Atsushi; Tokuda, Mamoru; Kato, Hisashi; Hasegawa, Kazuo; Uchiyama, Tatsushi; Matsubara, Shiro; Mori, Kazuma; Kimura, Hisashi; Shino, Kenji; Kato, Yasuchika; Ishii, Junichi.

In: Clinical and Experimental Hypertension, Vol. 36, No. 6, 01.10.2014, p. 433-440.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems

AU - Hiramitsu, Shinya

AU - Ishiguro, Yoshiaki

AU - Matsuyama, Hiroyuki

AU - Yamada, Kenji

AU - Kato, Kazuo

AU - Noba, Manji

AU - Uemura, Akihisa

AU - Matsubara, Yoshirou

AU - Yoshida, Satoshi

AU - Kani, Atsushi

AU - Tokuda, Mamoru

AU - Kato, Hisashi

AU - Hasegawa, Kazuo

AU - Uchiyama, Tatsushi

AU - Matsubara, Shiro

AU - Mori, Kazuma

AU - Kimura, Hisashi

AU - Shino, Kenji

AU - Kato, Yasuchika

AU - Ishii, Junichi

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Hyperuricemia is increasing in prevalence and this is paralleled by an increased incidence of acute gout. In addition, there is growing evidence of an association between high serum levels of uric acid (sUA) and cardiovascular disease (CVD). In this preliminary report, we present 12-16 week results from a multicenter, general practice study in which we evaluated the usefulness of febuxostat in a cohort of untreated patients with hyperuricemia with a high prevalence of CVD. Febuxostat titrated from 10 mg/day up to 40 mg/day resulted in statistically significant and clinically relevant reductions in sUA after 12-16 weeks. A "responder" level of 6.0 mg/dL or lower was achieved in 95 of 100 (95%) patients. Significant reductions in sUA were achieved regardless of the presence/absence of coexisting diseases (e.g. CVD, renal insufficiency, diabetes and obesity) or the class of antihypertensive agent being used by the patient. No serious adverse reactions were noted with febuxostat. Although allopurinol has been used generally for hyperuricemia/gout, it is excreted fully via the kidneys, restricting its use in patients with reduced renal function, and its three-times-daily administration leads to poor adherence. Based on the results of this study, febuxostat may provide an easier option than allopurinol for clinicians specializing in CVDs.

AB - Hyperuricemia is increasing in prevalence and this is paralleled by an increased incidence of acute gout. In addition, there is growing evidence of an association between high serum levels of uric acid (sUA) and cardiovascular disease (CVD). In this preliminary report, we present 12-16 week results from a multicenter, general practice study in which we evaluated the usefulness of febuxostat in a cohort of untreated patients with hyperuricemia with a high prevalence of CVD. Febuxostat titrated from 10 mg/day up to 40 mg/day resulted in statistically significant and clinically relevant reductions in sUA after 12-16 weeks. A "responder" level of 6.0 mg/dL or lower was achieved in 95 of 100 (95%) patients. Significant reductions in sUA were achieved regardless of the presence/absence of coexisting diseases (e.g. CVD, renal insufficiency, diabetes and obesity) or the class of antihypertensive agent being used by the patient. No serious adverse reactions were noted with febuxostat. Although allopurinol has been used generally for hyperuricemia/gout, it is excreted fully via the kidneys, restricting its use in patients with reduced renal function, and its three-times-daily administration leads to poor adherence. Based on the results of this study, febuxostat may provide an easier option than allopurinol for clinicians specializing in CVDs.

UR - http://www.scopus.com/inward/record.url?scp=84907031145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907031145&partnerID=8YFLogxK

U2 - 10.3109/10641963.2013.846358

DO - 10.3109/10641963.2013.846358

M3 - Article

C2 - 24164405

AN - SCOPUS:84907031145

VL - 36

SP - 433

EP - 440

JO - Clinical and Experimental Hypertension

JF - Clinical and Experimental Hypertension

SN - 1064-1963

IS - 6

ER -